Phathom Pharmaceuticals, Inc. (PHAT) - Q1 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2025. Phathom Pharmaceuticals is a biopharmaceutical company focused on gastrointestinal diseases, primarily commercializing VOQUEZNA (vonoprazan) for Erosive GERD, Non-Erosive GERD, and H. pylori infection. The company operates as a single reportable segment and is classified as a non-accelerated filer and smaller reporting company.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Product Revenue (Net) | $28.5 million | $1.9 million |
| Gross Profit | $24.8 million | $1.5 million |
| Gross Margin | 87% | 78% |
| Net Loss | $(94.3) million | $(82.9) million |
| Net Loss Per Share | $(1.31) | $(1.42) |
| Cash and Cash Equivalents | $212.3 million | $297.3 million (Dec 31, 2024) |
| Operating Cash Flow | $(84.9) million | $(69.0) million |
| Total Debt (Long-term) | $203.2 million | $201.4 million |
| Revenue Interest Financing Liability | $361.1 million | $353.0 million |
Material Changes vs. Prior Period
- Revenue Growth: Net product revenue increased by $26.6 million (1,392%) compared to Q1 2024, driven by the commercial launch of VOQUEZNA products initiated in late 2023.
- Operating Expenses: Total operating expenses rose by $32.2 million to $103.7 million. Selling, General, and Administrative (SG&A) expenses increased by $32.5 million, primarily due to a $28.3 million increase in advertising and promotional expenses.
- Interest Expense: Total interest expense increased to $18.1 million (from $17.2 million) due to higher debt balances and the accretion of the revenue interest financing liability.
- Liquidity: Cash and cash equivalents decreased by approximately $85 million during the quarter due to operating cash burn, despite strong revenue growth.
Outlook, Management Commentary, and Risks
- Restructuring Plan: On April 29, 2025, the Board approved a restructuring to reduce cash burn. This includes reducing direct-to-consumer promotion, suspending/deferring clinical programs (including the Phase 2 EoE trial), and reducing the workforce by 28 employees (~6%).
- Leadership Changes: Steven Basta was appointed CEO on April 1, 2025, replacing Terrie Curran. Additionally, the COO, Chief Commercial Officer, and CFO ceased serving in those roles effective April 30, 2025.
- One-Time Costs: The company expects to incur one-time restructuring costs of $7 million to $10 million, primarily recognized in Q2 2025. Separation costs for the former CEO are estimated between $2 million and $3 million.
- Liquidity Outlook: Management believes existing cash ($212.3 million) and anticipated revenues are sufficient to fund operations for at least the next 12 months.
- Supply Chain Risk: The company has been notified by supplier Sandoz of a potential disruption in the supply of clarithromycin tablets, a component of VOQUEZNA TRIPLE PAK. No commercial disruptions have occurred to date.
- Debt Covenants: The company is currently in compliance with all covenants under its Loan Agreement with Hercules Capital, though it does not expect to meet revenue thresholds to draw additional tranches.
Investor Verification Checklist
- Restructuring Impact: Verify the actual timing and magnitude of the $7M-$10M restructuring charges in the upcoming Q2 2025 filing.
- Supply Chain Status: Monitor updates regarding the potential clarithromycin supply disruption from Sandoz and its impact on VOQUEZNA TRIPLE PAK sales.
- Revenue Run Rate: Assess whether the Q1 revenue of $28.5M is sustainable given the decision to reduce direct-to-consumer promotion spending.
- Debt Service: Review the cash interest payments and the accretion of the revenue interest financing liability to ensure cash burn projections remain accurate.
- Leadership Transition: Evaluate the stability of the new executive team and the integration of the new CEO and CFO.